Researchers find older adults rarely discuss cannabis use with clinicians – Medical Xpress
✦ New CED Clinical Relevance #76 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. AgingResearchSafetyMental HealthPolicyPreventive MedicineFamily Medicine Why This Matters Older adults’…
Liraglutide vs Tirzepatide: Clinical Evidence for Weight Loss
This article reviews liraglutide vs tirzepatide weight loss clinical evidence, highlighting their mechanisms and outcomes. Tirzepatide shows superior weight reduction due to dual GIP/GLP-1 agonism. Understanding these differences aids optimal obesity and…
GLP-1 Weight Loss: Why Ozempic Results Often Stick
GLP-1 Clinical Relevance #39Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic CommentaryObservational StudyWeight Regain After DiscontinuationSemaglutideFamily…
GLP-1 Receptor Agonists: Clinical Evidence & Safety
GLP-1 Clinical Relevance #53Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical ReviewMetabolic MedicineWeight LossSemaglutideFamily MedicineAdults with…
Endocannabinoid System Research: Evidence-Based Cannabis Care in Family Medicine
This study evaluates a peer-supported mental health app designed to improve outcomes in university students. The app integrates evidence-based cannabis care principles within digital mental health interventions. Results suggest modest improvements in…
GLP-1 Weight Loss: Muscle Preservation Evidence
GLP-1 receptor agonist muscle preservation is a key factor in effective weight loss therapy. This approach helps maintain lean mass while reducing fat, improving metabolic health. Understanding muscle preservation during GLP-1 therapy is essential for…
GLP-1 Receptor Agonist Clinical Evidence: Tirzepatide Real-World Efficacy
Tirzepatide obesity management is supported by real-world clinical evidence demonstrating meaningful weight loss and tolerability. This study highlights tirzepatide’s effectiveness outside controlled trials. It provides valuable insights for clinicians…
GLP-1 Rebound Effects: Clinical Evidence & Weight Regain
GLP-1 rebound weight gain is a common clinical challenge after discontinuing therapy. Studies show many patients regain a significant portion of lost weight within a year. Understanding this phenomenon helps clinicians manage long-term weight outcomes…
GLP-1 Receptor Agonist Coverage: Medicare $50 Monthly
GLP-1 Clinical Relevance #46Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical NewsMedicare Coverage PolicyType 2 Diabetes and ObesityGLP-1 Receptor…
Oral Tirzepatide for Weight Rebound Prevention After GLP-1 Therapy
Oral tirzepatide weight rebound prevention offers a promising approach after discontinuing injectable GLP-1 therapy. Clinical evidence suggests it may reduce weight regain and support metabolic health. This strategy provides a potential bridge for…